- Home
- ONFO vs VIVS Comparison
ONFO vs VIVS Comparison
Compare ONFO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONFO | VIVS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | 27 | 9 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ONFO | VIVS |
|---|---|---|
| Price | $0.08 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 18.3M | 4.9M |
| Earning Date | 05-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.31 |
| 52 Week High | $2.48 | $5.30 |
Technical Indicators
Market Signals| Indicator | ONFO | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 23.93 | 19.23 |
| Support Level | N/A | N/A |
| Resistance Level | $0.59 | $1.62 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 17.26 | 1.47 |
Price Performance
Historical ComparisonAbout ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Pace Generative.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.